rHDL
PreclinicalSmall molecule
CSL BehringrHDL is one of 12 small molecule programs targeting Cholesterol. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Cholesterol
#DrugCompanyPhaseTrials
1Repatha
AmgenApproved
Zetia
OOrganon and Co
Approved
Crestor
AstraZenecaApproved
Plavix
SanofiPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Propolis
IIndonesia University
Phase 3
Cortrosyn
NovartisPhase 1
Acetylsalicyclic Acid (ASA)
BayerPhase 3
Decadron
AAspen Global Incorporated
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rHDL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company